Different functions, same mistake: a decision gap across GLP, GCP, and CSV

Let me try something with you.

Think about the last time a vendor made you uneasy. Not a formal finding, not something neatly written into an audit report. Just that sense that something wasn’t quite right. Maybe it was a lab result that didn’t line up, a system that behaved differently once it went live, or a study where confidence in the data felt thinner than it should.

Now ask yourself a slightly uncomfortable question: when did you actually decide to trust that vendor? Not when the audit happened, and not when QA reviewed the file, but when the organisation effectively committed.

I’ve been having variations of this conversation a lot recently, across preclinical teams, clinical operations, and CSV groups. Different settings and pressures, but the same pattern keeps showing up. A vendor is identified, often for sensible reasons. They’re known, available, or trusted by someone in the team. The study or project needs to move, so momentum builds. By the time QA is involved, the real decision has already been made. Not formally, perhaps, but practically. From that point on, everything shifts slightly. The audit still happens and the process is followed, but the question has changed from “Is this the right vendor?” to “How do we make this work?”

What’s interesting is that this doesn’t present as a failure. No one is deliberately cutting corners, processes often exist, and audits are still performed. On paper, everything looks reasonable, which is exactly why this is easy to miss.

It simply shows up differently depending on where you sit. In preclinical work, it often comes down to timing. You’ll see studies start with a vendor that feels familiar or low risk, with the intention of reviewing them properly later. The first meaningful audit then happens once data already exist. That does give you something valuable, because you’re not just reviewing procedures, you’re seeing real behaviour. But there is a trade-off sitting underneath that decision. If something fundamental is wrong, you are now dealing with it mid-study, with time, cost, and credibility already in play.

In clinical research, the pattern is less about timing and more about focus. There is usually strong attention on the obvious vendors, such as CROs and trial delivery partners. However, alongside them sit laboratories, PK providers, and specialist services generating data that directly inform outcomes. They do not always receive the same level of scrutiny, not because anyone believes they are unimportant, but because risk perception has not quite caught up with data impact.

In CSV, the pattern becomes even more explicit. A system is identified, demonstrations happen, and preferences form quickly. By the time QA is brought in, the conversation often sounds like, “We just need to get this through qualification,” rather than, “Should we be using this system at all?” Vendor qualification still happens, and the steps are followed, but the space to make a different decision has already narrowed.

So what is actually going on here? It is not poor auditing, lack of knowledge, or even weak processes. It is that decisions are being made before they are openly discussed. Once that happens, the rest of the system adapts around that reality. Audits become confirmation rather than influence, mitigations replace alternatives, and risk is managed but not always consciously accepted.

There is a simple way to spot this in real time. The next time a vendor is being discussed, listen carefully to the language being used. Is the conversation still open, or are you hearing phrases like “We’ve already decided,” “This is the only realistic option,” or “We just need QA to review it”? That is usually the signal, not that something has gone wrong, but that the true decision point has already passed.

This is not really about slowing things down or introducing more bureaucracy. It is about making one moment clearer. The moment where you decide how much uncertainty you are willing to carry, when you want to find out if something is not working, and what you would actually do if it is not. If that conversation happens early enough, the oversight model tends to take care of itself. If it does not, the model is effectively chosen for you.

If you wanted to test this in your own organisation over the next month, there are a few small shifts that can make a real difference. First, separate preference from commitment. It is completely natural for teams to have a preferred vendor early, but it is important to be explicit about when that preference becomes a commitment. Second, ask a slightly uncomfortable question before work starts:

under what circumstances would we walk away from this vendor?

If the honest answer is “none,” then the decision has already been made, whether it has been acknowledged or not. Third, define the last point of real choice. For each study or system, identify the point at which changing vendor is still realistic, then work backwards. Oversight needs to inform the decision before that point, not after it.

Across GLP, GCP, and CSV, we deal with different regulations, different data, and different types of complexity, but the underlying pattern is surprisingly consistent. We put a lot of effort into designing processes, yet spend far less time designing how decisions are actually made within them.

If you have read the main feature in this issue, you will have seen how different audit approaches reflect different levels of risk acceptance. This piece is simply the other side of that idea, because those choices are already being made in your organisation. The only question is whether they are being made deliberately, or quietly, in the background.

So here is something to reflect on. In your last study, system implementation, or vendor engagement, when was the last point you could genuinely have chosen a different path, and did your oversight approach reach that point in time, or arrive just after it?